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Abstract Since the advent of computed tomography,
numbers and expertise in Lymphangiography (LAG) have
markedly dropped. The intention of our study was to
demonstrate the persisting diagnostic and therapeutic im-
pact of LAG on the postoperative patient with known or
suspected lymphatic vessel leakage. Between May 1, 1999,
and April 30, 2006, we investigated pedal lipiodol-LAGs
(18 monopedal, 2 bipedal) on 22 patients (16 male, 6 fe-
male) with known or suspected postoperative chylothorax,
chylaskos, lymphocele, or lymphatic fistula. Ages varied
from 26 to 81 years. The spectrum of operative procedures
was broad: 6 thoracic, 5 abdominal, and 11 peripheral
operations were performed. In 20 patients who underwent
mono- or bipedal LAG for lymphatic vessel injury, we
were able to demonstrate the specific site of leakage in 15
cases (75%) and found signs of extravasation in 5 patients
(25%). Furthermore, in 11 patients (55%) we were able to
avoid surgery because of closure of the leak after LAG. As
the conservative therapeutic approach usually takes 2–3
weeks to reveal its therapeutic effects, 73.3% (11/15) of the
patients who were not reoperated before this hallmark was
passed did not need any further operation. Our study
clearly demonstrates that even in the decades of modern
cross-sectional imaging, classic LAG is a powerful and
highly reliable tool to visualize and even assist occlusion of
the postoperatively damaged lymphatic vessel and may
thereby avoid the need for reoperation.
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Introduction
Classic Lymphangiography (LAG), used for decades, has
the capability to detect internal architectural derangements
within normal-sized lymph nodes and, in addition, can
demonstrate and prove the lymphatic origin of a detected
fluid collection as seen in chylaskos, lymphocele, chylo-
thorax, or lymphatic fistula in the postoperative patient [1].
Using lipiodol as the contrast agent, its potential to induce
granulomatous reactions when extravasating has been
demonstrated [2] when assisted by additive procedures like
compression, drainage, and total parenteral nutrition [3–6].
The intention of our study was to demonstrate the diag-
nostic and therapeutic impact of LAG on the postoperative
patient with known or suspected lymphatic vessel leakage.
Materials and Methods
Between May 1, 1999, and April 30, 2006, we investigated
pedal lipiodol-LAGs (18 monopedal, 2 bipedal) on 22 pa-
tients (16 male, 6 female) with known or suspected post-
operative chylothorax, chylaskos, lymphocele, or
lymphatic fistula. Ages varied from 26 to 81 years. The
spectrum of operative procedures performed was broad: 6
thoracic, 5 abdominal, and 11 peripheral operations (Ta-
ble 1).
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The lymphatic vessel leakage had persisted for between
5 days and 22 weeks, when LAG was performed (Table 1).
In those cases with thoracic or abdominal drainage in
place, the daily amount of drainage ranged between 200
ml/d and 3 L/day. Therefore we monitored the sensitivity
of our LAGs to directly visualize the site of leakage and the
presence of abnormal lymphatic structures such as lym-
phoceles and fistulas or indirectly reveal a pathologic stop
of lipiodol distribution and contrast runoff into extracor-
poreal drainage reservoirs. In addition, we monitored the
outcome of conservative treatment of those conditions with
LAG, assisted by additive procedures such as compression,
drainage, and total parenteral nutrition.
All LAGs were performed with the written informed
consent of the patient and in the absence of contraindica-
tions. The patient is brought into a supine position with
bare feet. After local cutaneous disinfection (Braunoderm;
Braun), we inject a mixture of 2 ml of 1% Lidocaine and 2
ml of methylene blue dye (1% methylthionium chloride,
Methylenblau Vitis; Neopharma GmbH) into the cutaneous
and subcutaneous tissues of the first and second interdigital
space. After 10 min of exercising the foot the course of the
lymphatic vessels is identified through the skin. Via a
longitudinal cutaneous incision a vessel lateral to the base
of the first metatarsal is exposed, but also a more proximal
vessel near the ankle may be chosen. The surrounding
tissues are stripped, thereby giving good access to the
lymphatic vessel, which is then cannulated (De Roo nee-
dles Nos. 35 and 40 with spring and mandarin). Needle and
infusion line are secured with adhesive stripes (Steri-Strip;
3M Health Care). Once having secured access to the vessel,
we apply up to 1 ml/10 kg body weight per foot, not
exceeding a total volume of 14 ml of lipiodol (48%
iodinated glycerol ester), using an injector with an injection
speed of 4–7 ml/h per side. After the injection is completed
the materials are removed and the wound is cleansed, su-
Table 1 Indication and spectrum of operative procedures performed prior to LAG, resulting postoperative leakage type, and diagnostic/
therapeutic impact of LAG (diag./ther.)
Operative procedure Underlying disease/indication No.
cases
Leakage type Diag./ther. Duration
Pneumectomy Bronchial carcinoma 2 Chylothorax +/+ 11 days
TF 15 days
Nephrectomy Renal cell carcinoma 1 Chylaskos ++/+ 5 days
Polycystic kidney disease 1 Chylothorax (+) +/– 5 wk
Esophagectomy Esophageal carcinoma 2 Chylothorax ++/14 days 14 days
++/7 days 18 days
Melanoma 1 Chylothorax ++/21 days 13 days
Lymphadenectomy Melanoma 3 Lymph. fistula ++/+ 17 days
++/+ 12 days
TF 5 days
M. Hodgkin 1 Lymph. fistula +/+ 8 wk
Vulval carcinoma 1 Lymph. fistula (TF) ++/– 17 days
Penile carcinoma 1 Lymph. fistula ++/+ 6 days
Thymectomy Myasthenia gravis 1 Chylothorax ++/+ 6 days
Endoaneurysmoraphy Aneurysmal disease 1 Lymph. fistula ++/+ 22 days
1 Lymphocele ++/– 16 wk
Semicastration + retroperitoneal
lymphadenectomy





Prostatectomy Prostate carcinoma 1 Lymphocele ++/14 days 3 wk
Bypass
ACVB Coronary heart disease 1 Lymph. fistula ++/+ 22 wk
Fem-POP Peripheral artery occlusive
disease
1 Lymph. fistula +/4 days, for. body 6 wk
Partial gastrectomy Gastric carcinoma 1 Chylothorax +/+ 13 days
Soft tissue resection Thigh seroma 1 Lymphocele ++/– 6 wk
Note. +, indirect visualization; ++, direct visualization of the leakage site; days, reoperation at 4–21 days after LAG; lymph., lymphatic; TF,
technical failure; ( ), bipedal LAG; for. body, foreign body; re-exam. 8 wk, re-examination after 8 weeks; ACVB = CAVB; Duration of
lymphatic leakage before LAG was performed: 5 days–22 weeks
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tured, and covered with adhesive bands. Sutures may be
removed at postinterventional days 7–10. The application
is followed by complete fluoroscopic documentation of the
contrast runoff toward the venous angle (filling phase) plus
late-phase imaging after about 24 h (nodal phase). In cases
of cutaneous lymphatic fistulas the known cutaneous porus
is identified using an x-ray absorbent marker prior to
documentation.
Results
Of the 22 patients we intended to diagnose and treat we
initially failed to cannulate 2 (9.1%) for contrast-medium
application, one due to lymphedema and one due to very
thin and fragile lymphatic vessels. Twenty patients (90.9%)
underwent lipiodol-LAG (18 monopedal, 2 bipedal). Of the
20 patients who were lymphangiographied, 7 presented
with chylothorax, 8 with a lymphatic fistula, 3 with a
lymphocele, and 1 with chylaskos. In one case chylothorax
plus chylaskos was known.
LAG in 15 of these 20 (75.0%) patients directly deter-
mined the sites of femoral, thoracic, and abdominal con-
trast leakage, fistula, or lymphocele, respectively (Figs. 1–
3).
In five patients (25.0%) there were only indirect signs of
lymphatic vessel injury such as lipiodol detection in the
drainage reservoir (one case), pathologic disruption of the
centripetal contrast medium distribution with consecutive
masking of the extravasating lipiodol by dilution (two
cases), and atypical lymphatic vessels as a sign of lym-
Fig. 1 Chylothorax after esophagectomy in the case of esophageal
carcinoma. Leakage of the thoracic duct at the level Th6/Th7. Note
the extravasated lipiodol (arrows)
Fig. 3 Lymphatic fistula after resection of a melanoma of the right
thigh with additive inguinal and suprainguinal lymphadenectomy.
Note the lipiodol leakage (arrows)
Fig. 2 Lymphatic fistula of the left thigh after resection of a
melanoma of the first toe with additive inguinal and suprainguinal
lymphadenectomy. Note the extravasated lipiodol (arrows)
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phatic collateralization (two cases). Of the 20 patients who
were lymphangiographied, 11 (55.0%) needed no surgical
reintervention and the lymphatic leakage was stopped by
conservative treatment (e.g. additional compression,
drainage, and total parenteral nutrition) alone. Thoraco-
centeses, if used in the conservative approach, were re-
moved when drainage was <100 ml/day. Five of those 20
patients were operated before (4, 7, 14, 14, and 21 days
post-LAG) the completion of 3 weeks of conservative
treatment.
In the prostatectomy patient, the infected lymphocele
was surgically fenestrated and a Salem drainage was in-
serted 14 days after LAG. In the patient with the Fem-Pop
bypass, the foreign body (catheter fragment) that had been
documented by x-ray during LAG was removed and the
wound was debrided 4 days after LAG.
In the patient who underwent esophagectomy due to
melanoma, rethoracotomy and surgical occlusion of the
thoracic duct were performed at day 21 after LAG. In the
two patients who underwent esophagectomy for carcinoma
of the esophagus, rethoracotomy and surgical occlusion of
the thoracic duct followed at days 7 and 14 after LAG.
Eleven of 15 (73.3%) cases in which LAG and a further
conservative treatment regimen were not interrupted by
early surgery were cured with conservative treatment
alone.
In the subgroup analysis chylothorax (75%), chylaskos
(100%), chylothorax plus chylaskos (100%), and lymphatic
fistula (85.7%) showed very high rates of therapeutic suc-
cess without the need for further surgical intervention
(Table 2). In contrast, none of the three lymphocele cases
was treated sufficiently with conservative management
alone. Chylaskos, chylothorax plus chylaskos, and lym-
phocele were directly visualized in 100% of cases, com-
pared with 57.1% of the chylothoraces and 75% of the
lymphatic fistulas.
In one case the remaining part of a drainage catheter was
detected as a foreign body in the soft tissue of the thigh by
fluoroscopy, which led to early reoperation (day 4 after
LAG) with extraction of the foreign body and sealing of the
lymphatic fistula.
In the case with combined chylothorax and chylaskos
after semicastration and retroperitoneal lymphadenectomy
due to embryonic carcinoma, the initial LAG led to a
therapeutic success but recurrence of symptoms made a
diagnostically and therapeutically successful LAG neces-
sary after 8 weeks.
Discussion
The use of pedal LAG to demonstrate lymphatic vessel
leakage is well known. Sachs et al. clarified in 1991 that in
the case of LAG in patients with suspected laceration of the
thoracic duct, computed tomography is of little additional
value [7]. The spectrum of known sites of postoperative
lymphatic vessel leakage is broad, as seen in our study, and
may therefore lead to different manifestations such as
chylous ascites (a.k.a. chylaskos), chylothorax or even
chyluria, lymphocele, and lymphatic fistula [8–16]. It must
be emphasized that these manifestations may occur not
only postoperatively but also in the course of disease as a
complication or even congenitally [17, 18]. As of today
there are two major approaches to the therapy of identified
postoperative lymphatic vessel leakage: operative and
nonoperative treatment, with, e.g., the operative treatment
of chylothorax through thoracotomy having a high mor-
tality, up to 25% [19, 20].
Video-assisted thoracic surgery (VATS) may also be
used for clipping or ligation of the thoracic duct, as it is
safer and less invasive than open thoracotomy. However,
this procedure is not widely used, as a switch to the open
technique may be necessary if leakage visualization fails
endoscopically [21].
Spencer and Maloney initially recommended conserva-
tive treatment of chylothorax for at least 3–4 weeks before
considering surgery [22]. This was specified by Selle et al.,
who emphasized that cases with a daily drainage volume of
>1500 ml over 2 weeks should be surgically ligated earlier
[23].
In 1999 Cerfolio et al. pointed out that thoracostomy
drainage of >1000 ml/day for the first 7 days and the
Table 2 Diagnostic and therapeutic results of LAG in the types of lymphatic vessel leakage investigated
Chylothorax Chylaskos Chylothorax + chylaskos Lymphatic fistula Lymphocele
No. cases 7 1 1 8 3
Direct visualization 4/7 (57.1%) 1/1 (100%) 1/1 (100%) 6/8 (75%) 3/3 (100%)
Indirect visualization 3/7 (42.9%) — — 2/8 (25%) —
Therapeutic success 3/7 (42.9%) 1/1 (100%) 1/1 (100%) 6/8 (75%) 0/3 (0%)
Reoperation <4 wk after LAG 3/7 (42.9%) — — 1/8 (12.5%) 1/3 (33.3%)
Success without early reoperation 3/4 (75%) — — 6/7 (85.7%) 0/2 (0%)
Therapeutic failure 1/7 (14.3%) — — 1/8 (12.5%) 3/3 (100%)
S. Kos et al.: Lymphangiography 971
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development of a chylothorax after an esophageal opera-
tion were significant factors indicating an earlier need for
reoperation [5]. Most recently (2002) Cope and Kaiser
stated that in patients with unremitting or recurrent chyle
output of <500 ml/day, successful management is possible
with chest drainage and a low-fat diet, administered orally
or parenterally, with the favorable result being that the
chyle fistula seals off after 2–3 weeks, with or without
pleurodesis [24]. According to these data we chose a
maximum of 3 weeks as the upper threshold for a con-
servative therapeutic approach to determine its effects.
Conservative treatment in cases of chylothorax means
closed chest drainage or intermittent thoracocentesis sup-
ported by medium-chain triglycerides given orally or even
total parenteral nutrition. Persistent high output may be
treated with i.v. somatostatin-14 or etilefrin, pleurodesis, or
percutaneous embolization [3–6]. In cases of superficial
lymphocele or lymphatic fistula, external compression may
be included. Lu¨chtenberg et al. reported a case in which the
use of lipiodol in dacryocystography with complicating
perforation led to granulomatous reaction and consecutive
phlegmone, showing the potential of lipiodol to induce
inflammatory, granulomatous processes when extravasating
[2]. In cases which may not lead to occlusion of the perfo-
ration with conservative treatment alone, initial LAG is
further helpful by showing the surgeon the precise site and
height at which the lymphatic vessel ligation needs to be
performed, thereby simplifying preoperative planning and
reducing unexpected complications that may occur during
intraoperative exploration [25]. In addition, there are rare
cases described in which LAG in patients with known chy-
lothorax revealed spontaneous occlusion of the leaking
thoracic duct, making further surgical intervention unnec-
essary [25]. Our study proves that, at 75%, the sensitivity of
pedal lipiodol lymphangiograpy to directly determine the
sites of femoral, thoracic, and abdominal contrast leakage,
fistula, or lymphocele, respectively, is very good. In the
remaining 25% of cases, it was at least able to identify
lymphatic vessel injury. Having shown that 73.3% of the
patients who were treated conservatively and not reoperated
earlier than 3 weeks after LAG did not need any reoperation
at all, we confirm that LAG is a highly effective and powerful
tool even in a therapeutic approach. As shown in rare cases, it
may also reveal relevant pathologies (e.g., foreign bodies)
adjacent to the lymphatic system.
Apart for these advantages, we must mention that there
are strict contraindications for the procedure, such as pul-
monary insufficiency or right-to-left cardiac shunt, the first
being in risk of exacerbation by pulmonary embolism
through oil droplets, the latter creating the risk of cerebral
embolism [26]. LAG also should not be performed in cases
of lymphedema. Allergic reactions to patent blue dye have
been described, which may be treated with i.v. H1/H2-
anthistamines (clemastin, ranitidin) and i.v. steroids (me-
thyl-prednisolone) [27].
Conclusion
Our study clearly demonstrates that even in the era of modern
cross-sectional imaging, classic LAG is a powerful and
highly reliable tool to visualize and even assist occlusion of
the postoperatively damaged lymphatic vessel. Thereby, the
need for reoperation and exposure to perioperative mortality
may be avoided. Concerning the small numbers in our series,
especially in the subgroup analysis, of course, these results
are preliminary and need further confirmation.
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